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Abstract
The emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants is associated with accelerated
disease progression. CXCR4-using variants are believed to evolve from CCR5-using variants, but due to the extremely low
frequency at which transitional intermediate variants are often present, the kinetics and mutational pathways involved in
this process have been difficult to study and are therefore poorly understood. Here, we used ultra-deep sequencing of the
V3 loop of the viral envelope in combination with the V3-based coreceptor prediction tools PSSMNSI/SI and
geno2pheno[coreceptor] to detect HIV-1 variants during the transition from CCR5- to CXCR4-usage. We analyzed PBMC and
serum samples obtained from eight HIV-1-infected individuals at three-month intervals up to one year prior to the first
phenotypic detection of CXCR4-using variants in the MT-2 assay. Between 3,482 and 10,521 reads were generated from
each sample. In all individuals, V3 sequences of predicted CXCR4-using HIV-1 were detected at least three months prior to
phenotypic detection of CXCR4-using variants in the MT-2 assay. Subsequent analysis of the genetic relationships of these
V3 sequences using minimum spanning trees revealed that the transition in coreceptor usage followed a stepwise
mutational pathway involving sequential intermediate variants, which were generally present at relatively low frequencies
compared to the major predicted CCR5- and CXCR4-using variants. In addition, we observed differences between
individuals with respect to the number of predicted CXCR4-using variants, the diversity among major predicted CCR5-using
variants, and the presence or absence of intermediate variants with discordant phenotype predictions. These results provide
the first detailed description of the mutational pathways in V3 during the transition from CCR5- to CXCR4-usage in natural
HIV-1 infection.
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Introduction
The entry of human immunodeficiency virus type 1 (HIV-1)
into a target cell is dependent on the binding of the envelope
glycoprotein to its receptor CD4 and a coreceptor, either CCR5 or
CXCR4. Although the reasons are incompletely understood,
primary HIV-1 infection is predominantly established by CCR5-
using (R5) HIV-1 variants [1–4]. In approximately half of the
individuals infected with subtype B HIV-1, CXCR4-using (X4)
variants evolve from R5 viruses during the asymptomatic phase of
infection, and their emergence coincides with an accelerated
progression to AIDS [5–8]. This evolution from CCR5-usage to
CXCR4-usage often goes through intermediate variants that are
able to use both coreceptors. These R5X4 viruses can be further
classified according to the efficiency of their coreceptor usage as
Dual-R (more efficient use of CCR5) or Dual-X (more efficient use
of CXCR4) [9]. Pure R5 variants remain present after the
appearance of CXCR4-using variants, and in the vast majority of
HIV-infected individuals both virus populations co-exist during
the remaining course of infection [10,11].
Despite years of research, the mechanisms involved in the
appearance of CXCR4-using viruses remain to be fully under-
stood. The main determinants for coreceptor usage are located in
the second (V2) and third (V3) variable loop of Env [12–16], but
PLoS Pathogens | www.plospathogens.org 1 June 2011 | Volume 7 | Issue 6 | e1002106changes in C2 [17,18], C4 [19] and even in gp41 [17,20] have also
been reported to influence coreceptor usage. In particular,
positively charged amino acid residues at positions 11 and/or 25
of the V3 loop are highly associated with CXCR4-usage [21,22].
Although as few as one or two amino acid substitutions may be
sufficient to change coreceptor usage [22–24], the earliest
detectable CXCR4-using viruses in vivo show evidence of
additional, compensatory, mutations [25]. Together with a
decreased replication rate and reduced coreceptor efficiency of
intermediate variants [17,25,26], these findings suggest that the
transition from CCR5- to CXCR4-usage involves a phase of
markedly reduced viral fitness.
The presence or absence of CXCR4-using virus populations in
infected individuals can be monitored using phenotype-based
methods, such as the PBMC-based MT-2 assay [27,28] and the
plasma-based recombinant Trofile assay [29,30]. In addition,
genotype-based detection methods using signature changes in the
sequence of the V3 loop of CXCR4-using variants [21,22,31,32]
have been developed [33,34]. However, transitional intermediate
variants, which may be present at extremely low levels due to their
low replication capacity, are likely to be overlooked by standard
phenotype-based or genotype-based detection methods, which has
precluded their characterization and has hampered our under-
standing of the transition from CCR5- to CXCR4-usage.
As deep sequencing technologies can provide multiple orders of
magnitude greater coverage than conventional sequencing, we
used this technique in combination with V3-based coreceptor
prediction tools to detect HIV-1 variants during the transition
from CCR5- to CXCR4-usage. We previously carefully charac-
terized the first detection of CXCR4-using virus in ten HIV-1-
infected individuals using the MT-2 assay and the original and
enhanced-sensitivity Trofile assays on longitudinal PBMC and
serum samples [35]. Here, we analyzed PBMC and serum samples
obtained from the same group of subjects at three-month intervals
up to one year prior to the first phenotypic detection of CXCR4-
using variants in the MT-2 assay. The availability of thousands of
clonal sequences per sample obtained at relatively short intervals
allowed us to study the kinetics and mutational pathways involved
in the emergence of CXCR4-using variants.
Results
Comparison between Genotypic Prediction of HIV-1
Coreceptor Usage and In Vitro Coreceptor Phenotype
Determination
To determine whether we could use a V3-based prediction of
coreceptor usage to detect CXCR4-using variants by deep
sequencing on this set of HIV-infected individuals, we first
validated our prediction tools using V3 sequences with a known
coreceptor phenotype. To this end, recombinant viruses were
generated from 21–63 clonal env sequences that were isolated from
sera obtained from nine of our subjects (all individuals except DS6)
at several time points before, at, and after the moment at which
the MT-2 assay for the first time indicated the presence of
CXCR4-using variants (time point zero). These virus clones were
subsequently tested for their coreceptor usage in the Trofile assay
(Monogram Biosciences). All individuals harbored both R5 and
Dual-X variants at the later time points (Table S1 – S9). In
addition, the emergence of Dual-X variants was preceded by
Dual-R variants in five out of nine subjects (Table S1 – S9).
The coreceptor usage of the corresponding V3 sequences was
subsequently inferred using two different bioinformatic tools:
position-specific scoring matrix (PSSMNSI/SI) [33] and geno2phe-
no[coreceptor] (g2p) [34]. For all individuals except DS9 and DS10,
the phenotypes of (nearly) all R5 and Dual-X Env variants were
predicted correctly by both tools (i.e. nsi/r5 or si/x4, respectively;
Table 1 and Table S1 – S9). The three exceptions are one R5
variant and two Dual-R variants with predicted si/x4 phenotypes
in subject DS3 and subject DS8, respectively. On the other hand,
the V3 sequences of Dual-R Env variants were in general identical
to those of co-existing R5 variants, and were consequently
predicted to have an nsi/r5 phenotype. In addition, a subset of
R5 and Dual-R variants with identical V3 sequences from subject
DS8 had an si/r5 phenotype. Dual-R viruses showed much lower
infectivity on the CXCR4 cell line than on the CCR5 cell line, and
previous work has demonstrated that the determinants of
coreceptor usage in these viruses are most likely located outside
of the V3 region [9]. Because they could not be distinguished from
R5 viruses on the basis of V3 sequence, they were categorized as
CCR5-using variants for the purposes of this analysis.
In subject DS9, 57 of 60 (95%) virus variants were called nsi by
PSSM and x4 by g2p, irrespective of their in vitro phenotype
(Table 1 and Table S8), while the coreceptor usage of only three
clones was predicted correctly (nsi by PSSM and r5 by g2p). For
subject DS10, a large proportion of R5 viruses (42%) were
incorrectly predicted to be CXCR4-using by both PSSM and g2p
(Table 1 and Table S9). Assuming that the Trofile assay
reported the correct phenotype, the prediction tools could not
distinguish between phenotypically distinct variants in DS9 and
DS10, and these two individuals were therefore excluded from
further analysis.
Detection of Predicted CXCR4-Using V3 Sequences by
Ultra-Deep Sequencing
For the eight remaining subjects, V3 sequences were generated
from PBMC and serum samples obtained at three-monthly
intervals between 12 months before and time point zero by 454-
sequencing. Per sample, a median of 7,123 reads with a frequency
of $3 were obtained (range, 3,482–10,521; Tables 2 and 3). The
majority (median 70%; range, 33–100%) of sequences detected at
one time point with a frequency .10% in one compartment
(PBMC or serum) were also detected at the subsequent time point
in the same compartment (Figure S1). In general, the percentage of
sequences that were detected at two consecutive time points was
Author Summary
The first step in the infection of a target cell by human
immunodeficiency virus type 1 (HIV-1) is binding of the
envelope spike to its receptor CD4 and a coreceptor on the
cellular surface. HIV-1 variants present early in the course
of infection mainly use the coreceptor CCR5, while virus
variants that use CXCR4 can appear later in infection. This
change in coreceptor usage is associated with mutations
in the third variable (V3) loop of the envelope spike, but
has been difficult to study due to the low presence of
intermediate variants. Using ultra-deep sequencing, we
obtained thousands of sequences of the V3 loop from HIV-
1 infected individuals in the year before CXCR4-using
variants were first detected, including sequences from
almost all intermediate variants. We show that mutations
are introduced sequentially in the V3 loop during the
evolution from CCR5- to CXCR4-usage. Furthermore, we
describe differences and similarities between HIV-1-infect-
ed individuals that are related to this change in coreceptor
usage, which provides the first detailed overview of this
evolutionary process during natural HIV-1 infection.
Detection of X4 HIV-1 by Ultra-Deep Sequencing
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may reflect a lower input number of HIV copies in PBMCs and is
indicative of a larger sampling bias for PBMC samples. In addition, in
subjects DS6 and DS8 (who had relatively low viral loads) and DS2
(for whom viral load measurements were not available), the
percentage of sequences in serum that was detected at two con-
secutive time points was lower as compared to the remaining in-
dividuals. This was observed in particular for the sequences that were
present at low frequencies (,1%),although some sequences that were
not detected in serum were present in PBMC at the next time point.
The coreceptor use of V3 sequences obtained by ultra-deep
sequencing was subsequently inferred by PSSM and g2p. A high
degree of concordance was observed between the two algorithm
predictions among the V3 sequences of five subjects: DS1, DS2,
DS4, DS6, and DS7. In contrast, relatively large discrepancies
($15% of all reads per sample) between the predictions by PSSM
and g2p (i.e. nsi/x4 or si/r5) were observed for at least one sample
Table 1. Predicted phenotypes of Env clones for which
coreceptor usage was determined in the Trofile assay.
ACS ID Subject n clones
Phenotype
Trofile
Predicted phenotype
(PSSM/g2p)
a
H13912 DS1 15 R5 nsi/r5
6 Dual-X si/x4
H13988 DS2 49 R5 nsi/r5
3 Dual-X si/x4
H13845 DS3 26 R5 nsi/r5
1 R5 si/x4
20 Dual-R nsi/r5
1 Dual-R si/r5
15 Dual-X si/x4
H13951 DS4 36 R5 nsi/r5
6 Dual-R nsi/r5
12 Dual-X si/x4
H13993 DS5 42 R5 nsi/r5
9 Dual-X si/x4
H13885 DS6 n.a. n.t. n.t.
H13907 DS7 19 R5 nsi/r5
4 Dual-X si/x4
H13908 DS8 17 R5 nsi/r5
3 R5 si/r5
2 Dual-R nsi/r5
8 Dual-R si/r5
2 Dual-R si/x4
1 Dual-X si/r5
5 Dual-X si/x4
H13904 DS9 46 R5 nsi/x4
3 R5 nsi/r5
1 Dual-R nsi/x4
10 Dual-X nsi/x4
H13940 DS10 6 R5 nsi/r5
9 R5 si/r5
11 R5 si/x4
17 Dual-R si/x4
1 Dual-R si/r5
5 Dual-X si/x4
aCutoffs for PSSM and g2p were 21.75 and 3.5%, respectively.
ACS ID, subject identifier of Amsterdam Cohort Studies; n, number; n.a., not
applicable; n.t., not tested.
doi:10.1371/journal.ppat.1002106.t001
Table 2. CD4
+ T cell counts, viral load and MT-2 assay results
of participants DS1–DS4 around and during the period of
study.
Subject
Time to SI
(mo)
CD4+ T
cells/ml
blood
RNA load/
ml plasma MT-2
Reads
PBMC
Reads
serum
DS1 220.9 530 26,000 n.t. n.a. n.a.
218.0 590 n.t. NSI n.a. n.a.
214.5 800 n.t. NSI n.a. n.a.
211.7 520 n.t. NSI n.t. 5,754
28.3 450 42,000 NSI 3,660 8,659
26.0 390 n.t. NSI n.t. 3,482
23.0 410 n.t. NSI 5,383 3,497
0.0 570 n.t. SI 5,472 5,126
3.2 360 99,000 SI n.a. n.a.
6.1 300 n.t. SI n.a. n.a.
9.1 220 n.t. SI n.a. n.a.
DS2 219.3 480 n.t. NSI n.a. n.a.
215.2 340 n.t. NSI n.a. n.a.
212.2 460 n.t. NSI 9,840 6,589
28.9 300 n.t. NSI 8,098 8,135
25.8 440 n.t. NSI 8,570 5,138
22.8 580 n.t. NSI 6,932 5,489
0.0 480 n.t. SI 10,076 6,269
3.0 440 n.t. SI n.a. n.a.
6.0 280 n.t. SI n.a. n.a.
8.9 320 n.t. SI n.a. n.a.
DS3 29.2 800 23,000 NSI 6,064 5,731
26.0 990 n.t. NSI 9,027 6,482
23.0 1,230 120,000 NSI 9,364 7,448
0.0 890 100,000 SI 10,316 7,947
3.0 910 530,000 SI n.a. n.a.
6.0 650 1,300,000 SI n.a. n.a.
9.0 650 860,000 SI n.a. n.a.
DS4 221.1 710 n.t. fail n.a. n.a.
218.1 680 n.t. NSI n.a. n.a.
215.1 560 n.t. NSI n.a. n.a.
211.9 790 76,000 NSI 6,223 5,371
28.9 590 n.t. NSI n.t. 6,346
26.2 490 n.t. NSI 9,507 8,654
22.8 530 n.t. NSI 10,267 9,247
0.0 330 n.t. SI 10,521 6,550
3.0 400 n.t. SI n.a. n.a.
6.0 370 120,000 SI n.a. n.a.
9.3 230 n.t. SI n.a. n.a.
SI, syncytium-inducing; NSI, non-syncytium-inducing; mo, months; n.t., not
tested; n.a., not applicable.
doi:10.1371/journal.ppat.1002106.t002
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the percentage CXCR4-using HIV-1 variants, V3 sequences were
conservatively defined to be CXCR4-using when PSSM and g2p
were concordant in si/x4 prediction.
In these eight individuals, si/x4 sequences were detected at least
three months prior to phenotypic detection in the MT-2 assay and
were found as early as 12 months before time point zero in two of
eight subjects (Figure 1). In three individuals (DS1, DS2, and
DS6), these si/x4 variants were not detectable in PBMCs, which
has most likely precluded their detection in the PBMC-based MT-
2 assay. In total, in 13 of 27 PBMC samples obtained before time
point zero we detected the presence of si/x4 variants at levels
between 0.10% and 29% (median 1.2%). The inability of the MT-
2 assay to detect high levels of si/x4 variants may be a result of low
replication rates of these virus variants on the MT-2 cell line. In
addition, si/x4 variants were observed in 16 of 30 serum samples
obtained before time point zero. Of the serum samples obtained
before time point zero that were analyzed in the enhanced-
sensitivity Trofile assay (ESTA) and that were used for ultra-deep
sequencing (n=13), seven samples showed concordant results with
our genotypic data, while six samples that previously scored R5
were shown to contain si/x4 variants at levels between 0.13% and
2.5% (Figure 1). The sensitivity of the ESTA varied between
subjects, for example giving a positive result for the 23 months
serum sample from DS8 (0.4% si/x4 sequences) but a negative
result for the 23 month serum sample from DS5 (2.5% si/x4
sequences). This variation in detection limit is most likely the result
of differences between infectivity of viral envelopes from different
individuals on the U87 indicator cell lines.
Timing of Detection of Predicted CXCR4-Using V3
Sequences in Serum and PBMC
In four of eight individuals, V3 sequences with an si/x4
phenotype emerged in both serum and PBMC at the same time
point (Figure 1). In DS1 and DS6, the first si/x4 sequences were
detected in serum six months prior to the appearance of si/x4
sequences in PBMC at levels between 1.6 and 4.3%, while a very
small percentage of si/x4 sequences (0.1%) appeared in serum
three months before their detection in PBMC in subject DS2. In
contrast, si/x4 sequences (18.3% of the total number of reads)
were observed in PBMC three months earlier than in serum in
subject DS4. In general, the percentage of si/x4 sequences in both
serum and PBMC increased over time (Figure 2). In agreement
with previous findings [36,37], six of eight individuals showed a
higher prevalence of si/x4 sequences in PBMC (range, 2.7–66.0%)
than in serum (range, 0.6–49.1%) at time point zero, while si/x4
sequences were more abundant in serum (range, 14.0–40.6%) than
in PBMC (range, 13.4–14.5%) in the remaining two individuals.
Evolution of nsi/r5 Sequences to si/x4 Sequences
From each sample, we obtained several hundreds of unique V3
reads. We first constructed neighbor-joining (NJ) trees using all
unique reads obtained from the different time points and
compartments per individual to exclude contamination of samples
(data not shown). However, these trees were too large and too
complex to study the genetic relationship of our sequences, and
did not convey a good representation of the relative abundance of
each V3 sequence. Therefore, we subsequently constructed
minimum spanning trees (MSTs). MSTs are connection-type
networks which are based on a model explaining sequence
evolution in as few events as possible, similar to maximum
parsimony (MP) algorithms [38,39]. A MST thus represents the
shortest possible combination of nucleotide changes between all
sequences in the alignment. In contrast to most other methods for
Table 3. CD4
+T cell counts, viralload andMT-2assayresultsof
participants DS5–DS8 around and during the period of study.
Subject
Time to SI
(mo)
CD4+ T
cells/ml
blood
RNA load/ml
plasma MT-2
Reads
PBMC
Reads
serum
DS5 220.9 660 n.t. NSI n.a. n.a.
217.9 790 14,000 NSI n.a. n.a.
214.9 600 5,900 NSI n.a. n.a.
212.0 490 2,400 fail 10,239 8,881
29.0 530 6,100 NSI 8,932 8,734
26.0 450 6,100 NSI 9,623 9,585
23.0 410 7,600 NSI 8,906 9,083
0.0 520 17,000 SI 7,556 8,662
2.8 450 6,700 SI n.a. n.a.
5.6 480 80 NSI n.a. n.a.
8.8 580 3,600 NSI n.a. n.a.
DS6 218.5 660 n.t. NSI n.a. n.a.
215.3 440 n.t. NSI n.a. n.a.
212.1 330 n.t. NSI 6,959 7,671
29.1 310 2,100 NSI 7,500 7,772
26.1 460 n.t. NSI 7,287 6,320
23.2 470 n.t. NSI 7,645 5,945
0.0 470 n.t. SI 6,930 6,179
3.0 470 n.t. SI n.a. n.a.
6.0 310 10,000 SI n.a. n.a.
9.0 280 23,000 SI n.a. n.a.
DS7 219.9 780 n.t. n.t. n.a. n.a.
216.7 670 n.t. n.t. n.a. n.a.
213.7 490 n.t. n.t. n.a. n.a.
210.9 640 n.t. NSI 5,049 6,909
28.1 740 n.t. NSI 4,765 3,489
25.2 500 n.t. NSI n.t. 5,045
22.8 670 n.t. NSI 3,818 4,953
0.0 630 120,000 SI 6,901 5,139
3.2 510 n.t. SI n.a. n.a.
6.1 430 n.t. SI n.a. n.a.
9.1 380 n.t. SI n.a. n.a.
12.3 130 340,000 SI n.a. n.a.
DS8 219.9 520 n.t. n.t. n.a. n.a.
216.7 330 n.t. n.t. n.a. n.a.
212.5 420 n.t. NSI 9,901 6,666
210.7 390 n.t. NSI 6,184 6,835
27.1 430 n.t. NSI 9,706 7,641
23.0 400 n.t. NSI 10,169 8,292
0.0 270 n.t. SI 9,474 5,522
3.0 240 1,000 SI n.a. n.a.
4.1 320 n.t. SI n.a. n.a.
6.8 330 1,000 SI n.a. n.a.
9.7 190 5,800 SI n.a. n.a.
SI, syncytium-inducing; NSI, non-syncytium-inducing; mo, months; n.t., not
tested; n.a., not applicable.
doi:10.1371/journal.ppat.1002106.t003
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PLoS Pathogens | www.plospathogens.org 4 June 2011 | Volume 7 | Issue 6 | e1002106Figure 1. Detection of predicted CXCR4-using variants that emerge during natural HIV-1 infection using deep sequencing. For each
participant, the percentage si/x4 sequences in PBMC (light grey bars) and serum (dark grey bars) at time points up to one year before the first
phenotypic detection of CXCR4-using variants in the MT-2 assay are shown. Samples that have not been sequenced are indicated with an asterisk. In
the top of each graph, the results of the MT-2 assay and the enhanced-sensitivity Trofile assay (ESTA) are given: a blue bar indicates NSI or R5,
respectively, while a red bar indicates SI or D/M, respectively.
doi:10.1371/journal.ppat.1002106.g001
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not contain hypothetical internal nodes. This type of analysis
therefore requires all intermediate samples to be present in the
total pool of sequences. As a result, MSTs can only be used for the
analysis of sequences that show a limited degree of evolution and
that are sampled frequently enough, and are less suitable for the
analysis of, for example, full-length gp160 sequences in which a
multitude of nucleotide substitutions as well as large insertions and
deletions are observed over time. Due to these restrictions, MSTs
turned out to be a powerful tool to visualize the genetic
relationships between our closely related nsi/r5 sequences and
si/x4 sequences of the V3 loop (comprising 105 nucleotides) and to
identify intermediate sequence variants. Indeed, in the majority of
individuals, all intermediate variants between the major nsi/r5
variant and the major si/x4 variant were found, while a maximum
of two intermediate variants remained undetected in the other
individuals.
For each subject, one MST was constructed including V3
nucleotide sequences generated from all time points of both serum
and PBMC samples. A step-by-step explanation on how we read
and interpret these MSTs is presented in Figure 3 for subject
DS1, and a summary of our observations is shown in Table 4.I n
subject DS1, one nsi/r5 sequence dominated at all time points in
both serum and PBMCs, representing at least 30% (and up to
89%) of all sequences per time point. In addition, a population of
closely related si/x4 variants was observed, of which the first
variant appeared in serum at six months prior to the first positive
MT-2 time point. At the later time points, this variant was still only
detected in serum, while si/x4 variants with additional mutations
appeared in serum at the next time point and in PBMCs at time
point zero. Interestingly, the virus in subject DS1 required only
three mutations in V3 to change from the existing nsi/r5
phenotype at 212 months to an si/x4 phenotype, which were
introduced sequentially. After the introduction of the third of these
substitutions, replacing the serine residue at position 11 of the V3
loop by an arginine residue, the PSSM and g2p predictions
simultaneously switched from a CCR5-using inferred phenotype
to a CXCR4-using inferred phenotype.
Diversity in Major nsi/r5 Variants
Similar to subject DS1, relatively little sequence variation was
observed among the nsi/r5 variants in subjects DS4 (Figure S2),
and DS5 (Figure S3). In these individuals, eight or fewer major
amino acid sequence variants represented more than 80% of all nsi/
r5 reads for every time point and compartment (Table 4). Many of
these variants were present at multiple time points, and major shifts
in variants from one time point to the next were not observed. In
contrast, many different major nsi/r5 sequences (11 or more) were
present in subjects DS2 (shown as an example in Figure 4), DS3
(Figure 5), DS6 (Figure S4), DS7 (Figure S5) and DS8 (Figure
S6) both at any one time point and over time. For example, the
major nsi/r5 variant in PBMC at time point 212 months in subject
DS2 was completely replaced by other nsi/r5 variants three months
later, some of which in turn did not persist at the next time point. At
the later time points, the initial major nsi/r5 variant was observed
again, but at a lower frequency, while new sequence variants
continued to appear. Interestingly, the appearance of an si/x4
variant in this individual at time point zero was preceded by a
variant with a predicted nsi/x4 phenotype. The discrepancy
between the two phenotype prediction tools for this variant may
indicate that this sequence represents an intermediate step in the
pathway from R5-to-X4 evolution, as its score was relatively close to
thecutoffsforthePSSMandg2p(i.e.22.49and2.6%,respectively).
Alternatively, the phenotype of such intermediate variants may not
be predicted correctly as these variants are not often analyzed for
coreceptor usage in vitro and are therefore most likely not included in
the set of training sequences for the bioinformatic algorithms.
Intermediate nsi/x4orsi/r5 variantswerealsoobservedat relatively
low frequencies for subjects DS4 (Figure S2), DS5 (Figure S3),
and DS6 (Figure S4), whereas a major nsi/x4 variant was observed
in subject DS3 (Figure 5), and a major si/r5 variant was present at
all time points in subject DS8 (Figure S6).
Figure 2. Increasing percentage of predicted CXCR4-using variants over time following their appearance during natural HIV-1
infection. The median percentage si/x4 sequences generated from PBMC (light grey) and serum (dark grey) by deep sequencing at time points up to
one year before the first phenotypic detection of CXCR4-using variants in the MT-2 assay in eight participants are shown. Error bars represent the
interquartile ranges.
doi:10.1371/journal.ppat.1002106.g002
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While the MSTs of most individuals show only one si/x4
branch, multiple major si/x4 variants appeared in subjects DS3
and DS6. In DS3, two major si/x4 variants appeared at time point
zero, one of which was mainly found in serum, while the other was
mainly observed in PBMCs (Figure 5). These two variants
seemed to be highly related, and their distinct branches indeed
clustered in the NJ tree (data not shown). The MST shows a third
branch containing sequences with an inferred si/x4 phenotype.
However, the phenotype of an Env clone with the major V3
sequence from this branch was R5 in the Trofile assay (Figure 5),
suggesting that the prediction for sequences in this branch was
incorrect. In addition, several minor variants with an si/x4
prediction were observed at time points 29 months, 26 months,
and 23 months, none of which made up more than 0.15% of the
total number of reads per time point. These variants were not
detected at any other time point, suggesting that the fitness of these
variants was not sufficient to persist, or that they represent
sequences with PCR/sequence errors. In subject DS6, two major
si/x4 branches were observed, one of which represented an si/x4
variant that was detected in serum only (Figure S4). The second
branch contained the major si/x4 variant present in PBMCs at
time point zero, which was preceded by variants that again were
only found in serum.
In subject DS8, the first major si/x4 variant (frequency $10%
of all reads per time point) was observed at time point zero
(Figure S6). However, several minor si/x4 variants were detected
up to 12 months earlier (frequencies ,1.2%). Some of these minor
si/x4 variants were not related to the major si/x4 variant that
appeared later in infection, while others contained mutations that
were also found in the major si/x4 variant, such as an arginine
residue at positions 10 or 13 of the V3 loop. In subject DS2, two
minor si/x4 variants were observed in serum at time point 23
months (together comprising 0.11% of the total number of reads
from that sample), which were no longer detected at time point
zero when a third, apparently more successful si/x4 variant
(frequency .2% in PBMCs) emerged (Figure 4).
Discussion
The emergence of detectable CXCR4-using variants during
HIV-1 infection is a major determinant for disease progression,
but is still poorly understood. In this study, we provide a detailed
analysis of the kinetics and mutational pathways involved in the
appearance of CXCR4-using variants during natural infection
using V3 sequences generated by deep sequencing from PBMC
and serum samples of eight HIV-1-infected individuals, in
combination with V3-based coreceptor prediction tools, in the
year before CXCR4-using variants were for the first time detected
in the MT-2 assay.
Our sequence analyses show that the transition in coreceptor
usage from CCR5 to CXCR4 follows a stepwise mutational
pathway. In most subjects, we were able to detect all transitional
Table 4. Summary of the evolution of nsi/r5 sequences to si/x4 sequences obtained by ultra-deep sequencing.
Subject
Time point
first si/x4
variant
Compartment
first si/x4
variant
n major si/x4
branches
in MST
n major
nsi/r5
variants
a
Intermediate
nsi/x4 or
si/r5 variants
Minor
si/x4
variants
DS1 26 serum 1 3 no no
DS2 23 serum 1 11 yes yes
DS3 29 PBMC+serum 2 21 yes yes
DS4 23 PBMC 1 8 yes no
DS5 212 PBMC+serum 1 7 yes no
DS6 26 serum 2 14 yes no
DS7 23 PBMC+serum 1 11 no no
DS8 212 PBMC+serum 1 19 yes yes
aThe total number of major nsi/r5 variants that represents more than 80% of all nsi/r5 reads for each compartment at each time point. It is important to note that this
number of major nsi/r5 variants does not always correspond to the number of (relatively) large nodes in the MSTs. The nodes in the MSTs are often made up of
sequences from multiple time points and/or compartments, and the size of the node therefore does not always represent the frequency of the V3 sequence in an
individual sample.
doi:10.1371/journal.ppat.1002106.t004
Figure 3. Minimum spanning tree (MST) of V3 sequences from subject DS1. V3 sequences generated by deep sequencing were used to
construct MSTs. Identical nucleotide sequences are grouped in one node, and the circle size is proportional to the abundance of that particular V3
sequence. The length of the connecting branches corresponds to the number of nucleotide differences between the two connected nodes. Time
points are color-coded, using bright colors for PBMC samples and corresponding soft colors for serum samples. (A) MST stripped of sequences from
all time points except time point 212 months. For this time point, PBMCs were not available, and the MST thus consists of V3 sequences generated
from serum only (shown in light red). (B) V3 sequences from PBMCs (shown in bright orange) and serum (shown in light orange) obtained at time
point 29 months were added to the MST presented in panel A. (C) MST containing V3 sequences generated from 26 months serum (shown in light
yellow) in addition to the sequences present in the MST in panel B. (D) Sequences from PBMCs (bright green) and serum (light green) at timepoint 23
months have been added to the MST in panel C. (E) Complete MST containing PBMC and serum V3 sequences from all time points. V3 amino acid
sequences are shown relative to the majority sequence in PBMCs at the first time point (shown in blue box). Sequences of the major nsi/r5 variant,
the major si/x4 variant, and all intermediates are additionally shown in the bottom left. In all panels, nodes containing V3 sequences with an si
phenotype as inferred by PSSMNSI/SI and an x4 phenotype as inferred by geno2pheno[coreceptor] are indicated in red, all other sequences were
predicted to be nsi/r5. The phenotype of V3 sequences of which the corresponding Env clone was analyzed in the Trofile assay is given in bright blue
(for R5 sequences) or in bright red (for Dual-X sequences). Also shown are the results of phenotyping of PBMC samples by the MT-2 assay (NSI or SI)
and of serum samples by ESTA (R5 or D/M), and the percentages si/x4 sequences obtained from PBMC and serum samples by deep sequencing
(panel E, right side). N.t., not tested; mo, months.
doi:10.1371/journal.ppat.1002106.g003
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emerged in chronological order, indicating that the mutations
were introduced sequentially. Many intermediate variants were
present at much lower frequencies than the major nsi/r5 and si/x4
variants, indicative of a reduced replication capacity and
consistent with a model in which the transition from CCR5- to
CXCR4-usage involves the evolution of HIV-1 through a fitness
valley [17]. Alternatively, such variants may preferentially
replicate in other compartments than PBMCs or serum, which
could also explain their limited detection in our study. In
agreement with a study by Shankarappa et al. [40], we observed
a more rapid outgrowth of si/x4 viruses with a substitution at
position 11 of the V3 loop to more than 40% of the total number
of reads in PBMC at time point zero, as compared to si/x4 viruses
without a substitution at this position, indicating that specific
mutations in the V3 loop may affect replication kinetics.
Figure 4. Relatively large variation among major nsi/r5 variants over time in subject DS2. An MST of all V3 sequences generated from
PBMC and serum samples of all time points is shown. See the legend to Figure 3 for details regarding the layout of the figure. Nodes containing V3
sequences with an si phenotype as inferred by PSSMNSI/SI and an x4 phenotype as inferred by geno2pheno[coreceptor] are indicated in red, nodes
containing discordant nsi/x4 variants are indicated in light blue, while all other sequences were predicted to be nsi/r5. As Dual-X clones were not
detected in the Trofile assay until 18 months after the first MT-2
+ time point, the V3 sequences of two Dual-X clones from this later time point are
indicated in the top. These Dual-X sequences are closely related to the si/x4 sequences present at time point zero, suggesting that these si/x4
sequences indeed form the start of the major si/x4 branch in the tree. Mo, months; n.t., not tested.
doi:10.1371/journal.ppat.1002106.g004
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points is shown. See the legend to Figure 3 for details regarding the layout of the figure. Nodes containing V3 sequences with an si phenotype as
inferred by PSSMNSI/SI and an x4 phenotype as inferred by geno2pheno[coreceptor] are indicated in red, nodes containing discordant nsi/x4 variants are
indicated in light blue, while all other sequences were predicted to be nsi/r5. Two distinct si/x4 branches and several minor si/x4 variants can be
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restricted our analysis to the V3 loop, and prevented us from
investigating other changes in the viral envelope that may
influence coreceptor usage and viral fitness, in particular
substitutions in the V1V2 region that may compensate loss-of-
fitness mutations in V3 [18].
The specific mutational pathway that led to CXCR4-usage was
different for viruses from each individual, and is likely to be at least
partially constrained by the viral background. In subject DS3, we
observed the emergence of three different si/x4 variants, two of
which were closely related. The third predicted CXCR4-using
variant contained a different V3 loop, yet showed a similar
evolutionary pathway in which a substitution at position 25 of the
V3 loop was followed by the introduction of a glutamic acid at
position 24 (Figure 5). The same phenomenon was observed in
subject DS1, from which we also analyzed PBMC and serum
samples obtained three and six months after time point zero (data
not shown). At these later time points, we observed the appearance
of a second predicted CXCR4-using variant, unrelated to the
initial si/x4 variant that emerged nine months earlier, but with
identical amino acid substitutions at positions 10 and 11 of the V3
loop (data not shown). These observations support data suggesting
that the evolution in coreceptor usage is restricted by a limited
number of potential transitional pathways [17]. It will be
worthwhile to analyze the PBMC and serum samples from all
other subjects obtained three and six months after time point zero
to study the subsequent evolution of predicted CXCR4-using
viruses that were detected in this study, and to determine whether
new, unrelated predicted CXCR4-using variants, as observed in
subject DS1, appear in other individuals as well.
Despite constraints on the mutational pathways that lead from
CCR5- to CXCR4-usage and the low fitness of transitional
intermediate variants, CXCR4-using viruses eventually appear in
about 50% of subtype B HIV-1-infected individuals prior to the
development of AIDS [5]. The selective mechanisms driving
emergence of CXCR4-using variants are still not well understood,
and may include the accumulation of random mutations resulting
in a CXCR4-using virus with a high replicative fitness, or changes
in the host environment, such as immune pressure or the
availability of target cell (reviewed by Regoes et al. [41]). As we
only focused on evolution of the V3 loop during transition from
CCR5- to CXCR4-usage, we cannot draw any conclusions about
potential other factors involved in this process.
The use of deep sequencing in this study allowed us to detect
minority variants that would go unnoticed using conventional
sequencing techniques. In three of eight individuals, we observed
predicted CXCR4-using variants present at extremely low
frequencies. These variants may represent transitions from
CCR5- to CXCR4-usage that did not compete with a successfully
replicating CXCR4-using variant. However, even though we only
analyzed reads with a frequency of 3 or more, we cannot exclude
that some of these minority sequence variants may have resulted
from errors introduced during the PCR or sequencing procedures.
Variation in the major sequences detected among different
samples from one subject may to some extent be due to stochastic
founder events in the RT-PCR or PCR performed prior to ultra-
deep sequencing. We have attempted to minimize stochastic
sampling effects by performing the RT-PCR reactions for RNA
and the PCR reactions for DNA in triplicate and merging these in
equal quantities before ultra-deep sequencing. Sequence variants
with a frequency .1% in plasma were in general detected
longitudinally, indicative of accurate sampling of the major
variants in this compartment, while this was much less the case
for PBMC samples.
It is known that low-level CXCR4-using variants may be
selected upon CCR5 antagonist treatment [42–45], but it remains
to be determined whether their presence predicts the outgrowth of
a major CXCR4-using variant during natural infection or is of
pathological relevance in untreated individuals. A recent study in a
small number of HIV-1 individuals in whom low-level predicted
CXCR4-using variants were detected early in infection showed
that these variants could either persist or disappear over time [46].
To determine the relevance of these minority predicted CXCR4-
using variants, it would be worthwhile to additionally analyze
whether predicted CXCR4-using variants are also present in HIV-
infected individuals in whom phenotypic assays continue to detect
only CCR5-using variants. In addition, our results showed that the
emergence of predicted CXCR4-using variants was preceded by
variants with discordant phenotype predictions (nsi/x4 or si/r5) in
a subset of individuals. These viruses may represent intermediate
stages in the transition from CCR5- to CXCR4-usage. Analysis of
V3 sequences of HIV-1 from individuals in whom phenotypic
assays do not detect CXCR4-using viruses could also shed light on
the question whether the presence of such virus variants is
predictive for the appearance of CXCR4-using virus variants,
which would argue for combining the results of both predictors for
evaluation of patient samples.
The higher prevalence of CXCR4-using viruses in PBMCs
compared to serum as observed here and in previous studies
[36,37] suggests that the PBMC compartment may provide the
easiest source for the detection of CXCR4-using variants.
However, although CXCR4-using variants may preferentially be
present in a cell-associated state, we previously observed a good
concordance between phenotypic detection of CXCR4-using
variants in the MT-2 assay (using PBMCs) and the enhanced-
sensitivity Trofile assay (using serum). We here extend this finding
by showing that predicted CXCR4-using viruses are not generally
detected earlier in one compartment compared to the other. In
three of eight individuals, predicted CXCR4-using variants
emerged earlier in serum than in PBMCs, while these viruses
were first detected in PBMCs in one additional individual,
although a difference of one time point in the moment of
detection may also result from stochastic variation introduced
during sampling or subsequent experimental procedures. These
results indicate that analyzing both sources could contribute to the
enhanced accuracy of the detection of CXCR4-using viruses.
The recent availability of CCR5 antagonists as anti-HIV
therapeutics has highlighted the need to accurately identify
CXCR4-using variants in patient samples when considering use
of this new drug class. In this study, we show that coreceptor
phenotype prediction using V3 sequences generated by deep
sequencing allows a more sensitive detection of CXCR4-using
HIV-1 variants present at levels below approximately 2.5% of the
total virus population during natural infection as compared to the
phenotypic MT-2 assay and ESTA. In individuals treated with
maraviroc [47] or vicriviroc [48], minority CXCR4-using variants
present at less than 1% of the total pre-treatment HIV population
can be subject to positive selection and as a result cause virological
failure [45,49], indicating that this level of sensitivity may be
clinically relevant for the detection of minor CXCR4-using virus
observed in this MST, which are described in more detail in the text. In addition, one branch contains V3 sequences with a predicted si/x4 phenotype
which were reported R5 in the Trofile assay (indicated by dotted red oval). N.t., not tested; mo, months.
doi:10.1371/journal.ppat.1002106.g005
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CXCR4-using HIV-1 variants may however be limited by the
accuracy of the various bioinformatic tools for predicting the
correct coreceptor phenotype. For two of ten individuals initially
selected for this study, both PSSM and geno2pheno could not
distinguish between viruses with different in vitro phenotypes. In
subject DS9, determinants for coreceptor usage located outside the
V3 region were likely to be involved, as phenotypically distinct
clones had identical V3 loop sequences. Although some attempts
have been made, too few sequences with coreceptor determinants
outside V3 have been characterized to incorporate into a reliable
prediction algorithm. Moreover, due to the absence of minority
CXCR4-using variants in the training sets for these bioinformatic
algorithms, the phenotype prediction for low-level CXCR4-using
variants from clinical samples may not always be reliable [34].
Despite these shortcomings, recent data have shown that deep
sequencing combined with coreceptor prediction efficiently
predicts clinical efficacy of CCR5 antagonist therapy (Swenson et
al., CROI 2010). This suggests that relatively few individuals
harbor these minority and/or difficult to predict variants for a
significant period of time. However, improvement of the currently
available coreceptor prediction tools may be necessary.
In conclusion, our results show that HIV-1 evolves from CCR5-
to CXCR4-usage by the sequential introduction of mutations in
the V3 loop of the viral envelope. The observation that
intermediate variants were present at much lower frequencies
than the major CCR5- or CXCR4-using variants confirms that
this process is highly constrained by sequence and fitness
requirements of the virus, and may explain why CXCR4-using
variants, unlike CCR5-using variants, are not detected in all
patients at every stage of disease. These results provide a better
understanding of the emergence of CXCR4-using variants during
natural infection and may contribute to a more accurate detection
of CXCR4-using viruses in HIV-infected individuals for whom
CCR5 antagonist treatment is considered.
Materials and Methods
Ethics Statement
The Amsterdam Cohort Studies on HIV-1 infection and AIDS
(ACS) have been conducted in accordance with the ethical
principles set out in the Declaration of Helsinki, and written
informed consent was obtained prior to data and material
collection. The study was approved by the Academic Medical
Center institutional medical ethics committee.
Subjects
The individuals included in our present study were men who
have sex with men participating in the ACS who were seropositive
at enrollment into the cohort between 1988 and 1995. All subjects
were infected with subtype B HIV-1 and did not receive anti-
retroviral therapy at the time of sampling. In the ACS, cocultures
of peripheral blood mononuclear cells (PBMCs) from HIV-1-
infected individuals and the MT-2 cell line were routinely
performed for each visit at approximately three-months intervals
[27]. Ten subjects who reported at least three negative MT-2
scores in the 12 months prior to their first positive MT-2 assay
result (time point zero) were initially selected for this study, of
whom eight were analyzed in detail (Tables 2 and 3). In a
previous study, a high degree of concordance between the
detection of CXCR4-using virus variants in these individuals by
the MT-2 assay (using PBMCs) and the enhanced-sensitivity
Trofile assay (ESTA; using serum) was observed [35]. For better
readability, subject identifiers were recoded as DS1 (H13912), DS2
(H13988), DS3 (H13845), DS4 (H13951), DS5 (H13993), DS6
(H13885), DS7 (H13907), DS8 (H13908), DS9 (H13904), and
DS10 (H13940).
Samples
For each subject we performed deep sequence analysis on
plasma and/or PBMC samples collected every 3 months from 12
months prior to the first MT-2 positive time point (time point zero)
up to and including time point zero. For the plasma Env clone
genotype and in vitro phenotype analysis, plasma samples
collected after time point zero were also included.
Determination of In Vitro Coreceptor Phenotype
In the Trofile assay, a population of full-length subject-derived
env genes is amplified by reverse transcription-PCR and cloned
into an Env expression vector library that is used to generate
luciferase-reporter pseudoviruses [29]. These are subsequently
used to infect U87 target cells expressing CD4 and either CCR5 or
CXCR4 coreceptors in a 96-well plate format. Infection is
determined by assaying for luciferase activity in the presence
and the absence of CCR5 or CXCR4 antagonists, and viral
tropism is reported as R5, X4, or dual/mixed (D/M).
To determine the coreceptor phenotype of individual virus
variants present in virus populations of HIV-infected individuals, a
cloning step was introduced into the protocol by transforming the
Env expression vector library into competent cells. Multiple
functional env clones were subsequently isolated from randomly
picked bacterial colonies and were used to produce clonal
luciferase-reporter pseudoviruses. Between 7 and 13 clones per
serum sample were then tested in the Trofile assay to determine
coreceptor phenotype, which was reported as R5, X4 or Dual-
tropic. Dual-tropic viruses were further classified as Dual-R and
Dual-X variants. Both variants demonstrated infectivity on both
CCR5- and CXCR4-expressing cell lines which suppressed in the
presence of a specific antagonist. Dual-R variants however
demonstrated CXCR4 infectivity only at the lower end of
CXCR4 infectivity spectrum. Prior work has demonstrated that
the determinants of coreceptor usage in these viruses are most
likely located outside of the V3 region [9]. In addition, full-length
gp160 sequences were generated to determine the V3 genotype-
based prediction of coreceptor tropism (see details below).
DNA/RNA Extraction and Deep Sequencing
Deep sequencing was performed with minor adaptations to the
protocol as described previously by Swenson et al. [50]. HIV RNA
was extracted from previously frozen serum samples and HIV
DNA was extracted from cryopreserved PBMCs, both using a
NucliSENS easyMAG (bioMerieux, Marcy l’Etiole, France). The
RNA extracts underwent one-step RT-PCR in triplicate (4 ml
extract/reaction), while the DNA extracts underwent triplicate
first-round PCR. After the first-round PCR, the region encoding
the HIV V3 loop was amplified in a second-round PCR using
primers designed with Fusion Primers to fuse to the emulsion PCR
beads required by the 454 technique. Also included were 12
unique multiplex ‘‘barcode’’ sequence tags to enable the
identification of samples after the sequencing was complete. All
primers and thermal cycler protocols are listed in Protocol S1.
After PCR amplification, the concentrations of the PCR
products were quantified using a Quant-iT Picogreen dsDNA
Assay Kit (Invitrogen, Carlsbad, CA) and a DTX 880 Multimode
Detector (Beckman Coulter, Brea, CA). Triplicate PCRs were
then combined in equal proportions (2610
12 DNA amplicons
from each triplicate sample), purified with Agencourt Ampure
PCR Purification beads (Beckman Coulter), requantified, and
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5 molecules per ml. PCR
amplicons were then combined at a ratio of 0.6 molecules:1 DNA
capture microbead for emulsion PCR. Emulsion PCR was
performed, and the DNA and beads were washed, purified and
prepared for pyrosequencing according to the manufacturer’s
instructions. The DNA beads were then added onto the 454
pyrosequencing plate (divided into 4 regions) at a density of
250,000 beads per region, as quantified with a Z1 Coulter Particle
Counter (Beckman Coulter). The sequence amplified on each
bead was determined by pyrosequencing on the GS-FLX [49,51].
This process (using the standard amplicon GS-FLX technique)
generated ,250 base pairs of data in each direction per amplicon.
A typical V3 loop consisted of 105 base pairs (35 amino acids).
Truncated reads (defined as sequences missing $4 bases at the 59
or 39 end of the V3 loop) were not included in the analysis. To
reduce the number of sequences affected by PCR or sequencing
errors, reads with a frequency of 1 or 2 were excluded from the
dataset. The sequence alignments were subsequently inspected
manually, and reads containing ambiguous bases (Ns) or out-of-
frame insertions or deletions and reads that did not cover the
complete V3 region were removed. For all individuals except DS1,
a small number of sequences (on average 131 reads per individual,
range 46–387) did not cluster with the remaining sequences from
that subject in the neighbor-joining tree and/or minimum
spanning tree (see details below). In most patients, several
unrelated outliers were observed, both within a sample and across
samples from different time points, making it unlikely that these
may have been derived from a superinfecting virus variant present
at extremely low levels. Moreover, these sequences were in most
cases identical to one of the major V3 variants from another
subject, and were therefore deleted from the dataset as
contaminants.
Determination of Inferred Coreceptor Usage
HIV coreceptor usage was inferred from V3 genotype of each
individual sequence generated from the viral population of a
sample. Coreceptor usage inferences were made using the
bioinformatic algorithms position-specific scoring matrix
(PSSMNSI/SI) [33] and geno2pheno[coreceptor] (g2p) [34] scoring.
Non-genotypic factors such as CD4
+ cell count were not included
in the bioinformatic analysis. PSSM values below the predeter-
mined cutoff of 21.75 were called nsi, whereas those with scores
greater than or equal to 21.75 were called si. The g2p method
used a 3.5% false-positive rate, with samples categorized as r5 or
x4. These cutoffs were originally optimized and validated to
predict virologic outcomes on maraviroc using a separate dataset
of patients from three clinical trials of maraviroc in treatment-
experienced patients (McGovern et al., European AIDS conference
2009; Swenson et al., IDSA Annual Meeting 2009). The cutoffs can
be thought of as more ‘‘conservative’’ than the default cutoffs for
the algorithms. Note that the lowercase letters were used for these
classifications to indicate that tropism had been inferred from
genotypic data. Note also that nsi and si correspond roughly to r5
and x4, respectively. CXCR4-usage was conservatively defined to
be present when both algorithms were concordant in si/x4
prediction.
Phylogenetic Analysis
Unique forward and reverse nucleotide sequences from all time
points per subject from both PBMC and serum samples were
aligned using ClustalW in the software package of BioEdit [52],
and edited manually. The matrix of aligned nucleotide sequences
was imported into the tree building software PAUP* [53] (http://
paup.csit.fsu.edu/), and a neighbour-joining tree [54] was
constructed under the Hasegawa-Kishino-Yano (HKY85) model
of evolution [55]. We then used all forward and reverse V3
nucleotide sequences from all time points and compartments per
subject to construct minimum spanning trees. V3 sequences were
first aligned by the unweighted-pair group method using average
linkages (UPGMA) with BioNumerics 6.1 software (Applied
Maths). A minimum spanning tree was subsequently constructed
using a categorical coefficient. The Priority rules parameters were
set at the default values for every analysis, and hypothetical nodes
were not allowed. For increased readability, minor variants with a
non-si/x4 predicted phenotype present at only one time point and
in one compartment, and located in ‘dead-end’ branches were
removed from the tree.
Nucleotide Sequence Accession Numbers
V3 nucleotide sequences obtained by conventional sequencing
of Env clones tested in the Trofile assay are available from
GenBank (accession numbers JF507726 to JF508136). V3
sequences obtained by ultra-deep sequencing are available upon
request.
Supporting Information
Figure S1 Longitudinal detection of V3 sequences. For V3
sequences that were detected at low (,1%), intermediate (1–10%),
or high ($10%) frequencies at the first of two consecutive time
points, the percentage of sequences that is also detected at the next
time point is shown. For sequences detected in PBMCs at the first
of two time points, the lower light grey part of the bar indicates
sequences that were again detected in PBMC at the next time
point, while the upper dark grey part of the bar represents
sequences that were not detected in PBMCs but were instead
found in serum at the next time point. For sequences detected in
serum at the first of two time points, the lower dark grey part of the
bar indicates sequences that were again detected in serum at the
next time point, while the upper light grey part of the bar
represents sequences that were not detected in serum but were
instead found in PBMCs at the next time point.
(TIF)
Figure S2 MST of V3 sequences of subject DS4. This individual
shows a very linear evolution from CCR5- to CXCR4-using
variants with a stepwise introduction of mutations towards
CXCR4-usage. The earliest si/x4 sequence appears in PBMCs
at time point 23, and is replaced by an si/x4 variant with
additional mutations at time point zero. Only one si/x4 branch is
observed. In addition, relatively little variation occurs among the
major nsi/r5 variants over time. Mo, months; n.t., not tested.
(TIF)
Figure S3 MST of V3 sequences of subject DS5. In this
individual, a major si/x4 variant is already detected at time point
212 months and remains present at all subsequent time points.
Similarly, one major nsi/r5 variant is present at all time points in
both PBMCs and serum. Altogether, a relatively small number of
major nsi/r5 variants is observed, although some of these are
restricted to one time point and/or one compartment. The nsi/r5
and si/x4 branches of the tree are connected by an intermediate
variant with a predicted si/r5 phenotype. Mo, months; n.t., not
tested.
(TIF)
Figure S4 MST of V3 sequences of subject DS6. This individual
shows large variation in the major nsi/r5 variants, with many nsi/
r5 variants being present for only a short period of time or only in
one compartment. Originating from the same major nsi/r5
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which contain an intermediate variant with discordant phenotype
prediction (nsi/x4, indicated in light blue). Si/x4 variants are first
detected in serum at time point 26 months, and do not appear in
PBMCs until time point zero. Mo, months; n.t., not tested.
(TIF)
Figure S5 MST of V3 sequences of subject DS7. The first si/x4
variants in this individual are detected in PBMCs and serum at
time point 23 months. These minor variants are subsequently
replaced by a major si/x4 variant with additional mutations at
time point zero. Only one branch of si/x4 variants is observed in
this individual, and no discordant nsi/x4 or si/r5 sequences are
found. Mo, months; n.t., not tested.
(TIF)
Figure S6 MST of V3 sequences of subject DS8. In contrast to
all other individuals where si/x4 variants are only located in
external branches of the tree, the major si/x4 branch in the MST
of this subject originates from an internal node. This internal si/x4
variant is already present at time point 26 months. Moreover,
several minor si/x4 variants are detected as early as time point
212 months, but most of these do not persist at the later time
points. A major variant present at all time points has a predicted
si/r5 phenotype. The phenotype of Env clones with this V3
sequence was R5 (n = 2) or Dual-R (n=8) in the Trofile assay. In
addition, the phenotype of an Env clone corresponding to the
node branching off this major variant at the top left side (with an
additional substitution at position 27 of the V3 loop) was Dual-X,
while it phenotype was predicted to be si/r5. Mo, months; n.t., not
tested.
(TIF)
Table S1 Predicted phenotypes and V3 sequences of longitudi-
nally isolated Env clones of subject DS1 for which coreceptor
usage was determined in the Trofile assay.
(PDF)
Table S2 Predicted phenotypes and V3 sequences of longitudi-
nally isolated Env clones of subject DS2 for which coreceptor
usage was determined in the Trofile assay.
(PDF)
Table S3 Predicted phenotypes and V3 sequences of longitudi-
nally isolated Env clones of subject DS3 for which coreceptor
usage was determined in the Trofile assay.
(PDF)
Table S4 Predicted phenotypes and V3 sequences of longitudi-
nally isolated Env clones of subject DS4 for which coreceptor
usage was determined in the Trofile assay.
(PDF)
Table S5 Predicted phenotypes and V3 sequences of longitudi-
nally isolated Env clones of subject DS5 for which coreceptor
usage was determined in the Trofile assay.
(PDF)
Table S6 Predicted phenotypes and V3 sequences of longitudi-
nally isolated Env clones of subject DS7 for which coreceptor
usage was determined in the Trofile assay.
(PDF)
Table S7 Predicted phenotypes and V3 sequences of longitudi-
nally isolated Env clones of subject DS8 for which coreceptor
usage was determined in the Trofile assay.
(PDF)
Table S8 Predicted phenotypes and V3 sequences of longitudi-
nally isolated Env clones of subject DS9 for which coreceptor
usage was determined in the Trofile assay.
(PDF)
Table S9 Predicted phenotypes and V3 sequences of longitudi-
nally isolated Env clones of subject DS10 for which coreceptor
usage was determined in the Trofile assay.
(PDF)
Protocol S1 Primers and thermal cycler protocols for amplifi-
cation of the HIV V3 region prior to 454-sequencing.
(PDF)
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